drugset / Trial / NCT00099268

Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy

NCT00099268

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.

Timeline

Start
2004-09
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Entacapone Small molecule 200 mg Oral
Comparator Carbidopa Unknown 12.5 mg Oral
Comparator Carbidopa Unknown 25 mg Oral
Comparator Levodopa Small molecule 50 mg Oral
Comparator Levodopa Small molecule 100 mg Oral

Indications